Development of the Serum ?-Fetoprotein Reference Range in Patients with Beckwith-Wiedemann Spectrum - 19/08/19
Abstract |
Objective |
To establish reference ranges for serum α-fetoprotein (AFP) at various ages in patients with Beckwith-Wiedemann spectrum (BWSp), to better predict the risk for hepatoblastoma in this population.
Study design |
A retrospective analysis of AFP measurements collected from patients with BWSp was performed. Factors including sex, prematurity, molecular diagnosis of patients, and performing laboratory were evaluated for significant differences. In total, 1372 AFP values were collected from 147 patients and the predictive AFP values at various ages were calculated to establish reference ranges. Mixed-effects polynomial regression models were used to study various potential factors affecting log(AFP) values.
Results |
Overall, predicted AFP values declined to normal range for age (<10 ng/mL) by 14 months old. Patient sex and performing laboratory were found not to influence values. A significant difference was demonstrated between premature and nonpremature patients, and separate reference values were established. Significant differences in the predicted AFP value were not broadly apparent between molecular subtypes; however, interpretation was limited due to the small sample size of some of these subtypes.
Conclusions |
Predictive AFP values were created for premature and nonpremature patients with BWSp to aid with interpretation and monitoring of the risk for hepatoblastoma. Further analysis is needed to determine whether AFP values differ within the less common molecular subtypes of patients with BWSsp.
Le texte complet de cet article est disponible en PDF.Keywords : tumor screening, hepatoblastoma
Abbreviations : AFP, BWS, BWSp, IC1 GOM, IC2 LOM, ILO, pUPD
Plan
Alex's Lemonade Stand Foundation (to J.K.), the National Institutes of Health (K08 CA193915 [to J.K.]), St. Baldrick's Foundation (to J.K.), and the Orphan Disease Center in the Perelman School of Medicine at the University of Pennsylvania (to J.K.). J.C. served as a consultant for Sobi, Inc. The other authors declare no conflicts of interest. |
Vol 212
P. 195 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?